Name of License: Notice of Intent to Grant an Exclusive License to ResQ Pharma
Summary: Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to ResQ Pharma, Inc., 2242 W. Harrison St., Ste. 201, Chicago, Illinois 60612, an exclusive license to VA’s rights in International Patent Application Nos. PCT/US2018/012623 and PCT/US2019/033997 and U.S. Patent Application Nos. 16/476,404 and 17/058,545 and all foreign counterparts, associated with VA Invention Disclosure numbers 2020-096 and 2020-147 titled, “Methods for Decreasing Injuries Associated with Intraoperative Hypotension” and “Lipid Emulsions and Uses Thereof”.
Tech Name:
Lipid emulsions and uses thereof
Dates: Comments must be received on or before August 31, 2021.
Address: Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), [email protected].
For Further Information Contact: Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), [email protected].
Supplementary Information: The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.